Literature DB >> 26485209

NaoXinTong Inhibits the Advanced Atherosclerosis and Enhances the Plaque Stability in Apolipoprotein E Deficient Mice.

Xiaoxiao Yang1, Lei Sun, Yan Li, Chuanrui Ma, Jie Yang, Wenwen Zhang, Buchang Zhao, Lifu Jia, Yajun Duan, Jihong Han, Xiaoju Li, Yuanli Chen.   

Abstract

Buchang NaoXinTong (NXT), a Chinese medicine, has been widely used to treat patients with coronary heart disease in China. However, the underlying mechanisms need more elucidations. In this study, we investigated if NXT can inhibit the progression of the established lesions while stabilizing plaques. Apolipoprotein E deficient (apoE(-/-)) mice in 3 groups received following treatment: group 1 was fed a high-fat diet (HFD) for 18 weeks; group 2 was prefed HFD for 12 weeks followed by HFD containing NXT for additional 6 weeks; group 3 was prefed HFD for 8 weeks followed by HFD containing NXT for additional 10 weeks. After treatment, serum and aorta samples were collected and determined lipid profiles, lesions, collagen content, mineralization, and macrophage accumulation in aortic root, respectively. NXT had slight effect on serum lipid profiles but significantly reduced progression of the advanced lesions. In aortic wall, NXT increased smooth muscle cell/collagen content in lesion cap while reducing buried fibrous caps, mineralization, and macrophage accumulation within lesions, which suggests that NXT can stabilize plaques. In addition, NXT increased expression of smooth muscle 22α mRNA while inhibiting expression of matrix metalloproteinase-2 and tumor necrosis factor α mRNA in aortas. Our study demonstrates that NXT can reduce advanced atherosclerosis and enhance the plaque stability in apoE(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26485209     DOI: 10.1097/FJC.0000000000000334

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Chinese Experts Consensus on Clinical Application of Naoxintong Capsule ().

Authors:  Liu Long-Tao
Journal:  Chin J Integr Med       Date:  2018-04-14       Impact factor: 1.978

Review 2.  Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.

Authors:  Zhuo-Ming Li; Suo-Wen Xu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

Review 3.  Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review.

Authors:  Shiqi Chen; Xiaoxiao Wu; Tong Li; Yang Li; Baofu Wang; Weiting Cheng; Yu Teng; Jingjing Yang; Hui Meng; Lei Wang; Ziwen Lu; Yangyang Jiang; Yahong Wang; Mingjing Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-27       Impact factor: 2.629

4.  Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit.

Authors:  Yanfen Cheng; Meng Xiao; Jiamei Chen; Di Wang; Yichen Hu; Chenfeng Zhang; Tuanjie Wang; Chaomei Fu; Yihan Wu; Jinming Zhang
Journal:  Chin Med       Date:  2022-09-02       Impact factor: 4.546

5.  The Effect of Naoxintong Capsule in the Treatment of Patients with Cerebral Infarction and Carotid Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Qiuer Liang; Yunfei Cai; Ruixue Chen; Weihao Chen; Liguo Chen; Ya Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-24       Impact factor: 2.629

6.  NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice.

Authors:  Shu Yang; Mengyang Liu; Yuanli Chen; Chuanrui Ma; Lipei Liu; Buchang Zhao; Yong Wang; Xiaoju Li; Yan Zhu; Xiumei Gao; Deling Kong; Yajun Duan; Jihong Han; Xiaoxiao Yang
Journal:  Sci Rep       Date:  2018-06-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.